EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Belzutifan-Associated Hypoxia: A Review of the Novel Therapeutic, Proposed Mechanisms of Hypoxia, and Management Recommendations

John Kucharczyk iD, Anshini Bhatt iD, Laura Bauer, Minas Economides

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26157094 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von John Kucharczyk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Hematology, Perlmutter Cancer Center at NYU Langone Hospital-Long Island, Mineola, NY 11501, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Hypoxia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Belzutifan is a hypoxia-inducible factor-2α (HIF-2α) inhibitor that received FDA approval in 2021 for treating cancers resulting from von Hippel-Lindau (VHL) disease, including clear cell renal cell carcinoma (ccRCC), followed by approval in 2023 for sporadic ccRCC that has progressed through multiple lines of therapy. HIF-2α is a promising drug target, as VHL is commonly inactivated in ccRCC, which results in HIF-2α-mediated signaling that is considered central to tumorigenesis. Belzutifan has demonstrated efficacy in clinical trials in the first-line and subsequent line settings, and in combination with tyrosine kinase inhibitors. Despite being overall well tolerated, belzutifan has a distinct safety profile because of its unique mechanism of action. Anemia was the most common adverse event observed in clinical trials and is considered an on-target effect. Hypoxia is also frequently observed and commonly results in dose reductions, treatment discontinuation, and supplemental oxygen use. This review summarizes the rates of hypoxia seen in clinical trials of belzutifan in ccRCC. As the cause of hypoxia is not well understood, this review also discusses possible mechanisms of hypoxia based on preclinical studies of the HIF pathway and HIF-2α inhibitors. Finally, this review proposes monitoring and management recommendations for clinicians prescribing belzutifan to ccRCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHypoxiaHumansBasic Helix-Loop-Helix ProteinsAnimalsvon Hippel-Lindau DiseaseIndenesEndothelial PAS Domain-Containing Protein 1

Stichwörter der Autor:innen

adverse eventsbelzutifanhypoxiahypoxia-inducible factor-2α (HIF-2α)renal cell carcinoma

Substanzen

Basic Helix-Loop-Helix ProteinsIndenesEndothelial PAS Domain-Containing Protein 1belzutifan

Autor:innen und Institutionen

  • Department of Oncology and Hematology, Perlmutter Cancer Center at NYU Langone Hospital-Long Island, Mineola, NY 11501, USA.
  • Department of Genitourinary Medical Oncology, Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016, USA.

ORCID-Profile: John Kucharczyk, Anshini Bhatt

Zitieren

APA

Kucharczyk, J., Bhatt, A., Bauer, L., & Economides, M. (2025). Belzutifan-Associated Hypoxia: A Review of the Novel Therapeutic, Proposed Mechanisms of Hypoxia, and Management Recommendations. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157094

Vancouver

Kucharczyk J, Bhatt A, Bauer L, Economides M. Belzutifan-Associated Hypoxia: A Review of the Novel Therapeutic, Proposed Mechanisms of Hypoxia, and Management Recommendations. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157094

BibTeX
@article{Kucharczyk2025,
  author = {Kucharczyk, John and Bhatt, Anshini and Bauer, Laura and Economides, Minas},
  title = {Belzutifan-Associated Hypoxia: A Review of the Novel Therapeutic, Proposed Mechanisms of Hypoxia, and Management Recommendations},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26157094}
}
Kostenlos starten →